- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04533022
Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects With Idiopathic Pulmonary Fibrosis
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Kamilla Overbeck Nygaard, MSc
- Phone Number: +46 (0) 317880560
- Email: kamilla.overbeck@vicorepharma.com
Study Contact Backup
- Name: Rohit Batta, MD
- Phone Number: +46 (0) 317880560
- Email: rohit.batta@vicorepharma.com
Study Locations
-
-
-
Kanpur, India, 208001
- Apollo Spectra Hospitals (Apollo Speciality Hospital Pvt. Ltd.)
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380008
- AMCMET Medical College and Sheth LG General Hospital
-
Surat, Gujarat, India, 395010
- Unity Hospital
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400007
- The Bhatia Hospital
-
Mumbai, Maharashtra, India, 400008
- Grant Government Medical Collage and Sir J.J. Group of Hospitals
-
Nagpur, Maharashtra, India, 440019
- N. K. P. Salve Institute of Medical Sciences & Research Centre and Lata Mangeshkar Hospital
-
Pune, Maharashtra, India, 411004
- Ace Hospital & Research Center
-
Pune, Maharashtra, India, 411005
- Oyster & Pearl Hospitals
-
-
Tamilnadu
-
Coimbatore, Tamilnadu, India, 641028
- Hindusthan Hospital
-
-
Uttar Pradesh
-
Alīgarh, Uttar Pradesh, India, 202002
- Jawaharlal Nehru Medical College - Aligarh Muslim University
-
Lucknow, Uttar Pradesh, India
- Midland Healthcare and Research Centre
-
-
-
-
-
Yaroslavl, Russian Federation
- Clinical Hospital for Emergency Medical Care n.a. N.V. Solovyev
-
-
-
-
-
Kharkiv, Ukraine, 61124
- MNCE City Clinical Hospital
-
Lviv, Ukraine, 79010
- Lviv National Medical University
-
Odessa, Ukraine, 65025
- Odessa Regional Hospital
-
Vinnytsia, Ukraine, 21001
- Private Small Scale Enterprise Medical Center 'PULSE'
-
-
-
-
-
Birmingham, United Kingdom, B15 2TH
- University Hospital Birmingham
-
London, United Kingdom, SW3 6NP
- Royal Brompton Hospital
-
London, United Kingdom
- University College Hospital
-
London, United Kingdom
- University College London Hospitals
-
Manchester, United Kingdom, M23 9QZ
- Medicines Evaluation Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent, consistent with ICH-GCP R2 and local laws, obtained before the initiation of any trial related procedure
- A diagnosis of IPF within 5 years prior to Visit 1, as per either ATS/ERS/JRS/ATLAT/Fleischner guidelines
- Age ≥40 years
- FVC ≥60% predicted at Visit 1 (specifically for UK: FVC ≥80% predicted at Visit 1)
- FEV1/FVC ratio ≥0.7 prebronchodilator at Visit 1
- Oxygen saturation (SpO2) >85% by pulse oximetry while breathing ambient air at rest at Visit 1
High-resolution computed tomography (HRCT) within 36 months prior to Visit 1 with central reading demonstrating either a or b, and c:
a. A pattern consistent with usual interstitial pneumonitis (UIP) according to ATS/ERS/JRS/ALAT or Fleischner guidelines i. UIP ii. Probable UIP or b. A pattern indeterminate for UIP according to either ATS/ERS/JRS/ALAT or Fleischner guidelines and a historical biopsy consistent with IPF c. Extent of fibrosis > extent of emphysema
- Fully vaccinated against COVID-19 prior to screening (Visit 1). Subjects are considered fully vaccinated for COVID-19 ≥14 days after they have received vaccination dose(s) according to local label
Exclusion Criteria:
- Previous use of antifibrotic treatment for an interstitial lung disease (e.g. nintedanib or pirfenidone) for > 6 months
- Smoking (including e-cigarettes) within 6 months prior to Visit 1
- Body mass index (BMI) >35 or <18
IPF exacerbation within 3 months prior to Visit 1:
- Acute worsening or development of dyspnoea typically <1 month duration
- Computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia pattern (if no previous computed tomography is available, the qualifier "new" can be dropped)
- Deterioration not fully explained by cardiac failure or fluid overload
- Concurrent serious medical condition with special attention to cardiac or ophthalmic conditions (e.g. contraindications to cataract surgery) which in the opinion of the investigator makes the subject inappropriate for this trial
- Malignancy within the past 5 years with the exception of in situ removal of basal cell carcinoma and cervical intraepithelial neoplasia grade I
Treatment with any of the medications listed below within 4 weeks prior to Visit 1:
- Cytochrome p450 (CYP) 3A4 inducers (e.g. rifampicin, phenytoin, St. John's Wort)
- CYP3A4 inhibitors (e.g. clarithromycin, ketoconazole, nefazodone, itraconazole, ritonavir)
- Medicines that are substrates of CYP1A2, CYP3A4 or CYP2C9 with a narrow therapeutic range
- Experimental drugs
- Any systemic immunosuppressive therapies other than:
- Inhaled corticosteroids which can be used throughout the trial period provided the dose is kept stable
- Corticosteroids for the treatment of acute exacerbations
- The continuation of stable doses of ≤15 mg daily doses of prednisolone
Treatment with any of the medications listed below within 2 weeks prior to Visit 1:
- Proton pump inhibitors (PPI's) more than once daily
- Histamine H2 receptor antagonists (H2RA's)
- Sulphasalazine and rosuvastatin
- High dose breast cancer resistance protein sensitive substrates (other than sulphasalazine or rosuvastatin)
Any of the following findings at Visit 1:
- Prolonged QTcF (QT interval with Fridericia's correction) (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG, as judged by the Investigator
- Positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb) or human immunodeficiency virus 1+2 antigen/antibody (HIV 1+2 Ag/Ab)
- Positive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin)
- Inability to generate lung function data at Visit 1 meeting the minimum standards of the ATS/ERS 2005 guideline, as determined by central review
- Clinically significant abnormal laboratory value at Visit 1 indicating a potential risk for the subject if enrolled in the trial as evaluated by the investigator
- Pregnant or breast-feeding female subjects
- Female subjects of childbearing potential not willing to use contraceptive methods
- Male subjects not willing to use contraceptive methods
- Subjects not willing to adhere to dietary restrictions during the trial period
- Participation in any other interventional trial during the trial period
- Subjects known or suspected of not being able to comply with this trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
- Discontinuation or change of previous antifibrotic treatment (e.g. nintedanib or pirfenidone) due to disease progression
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: C21
|
C21 b.i.d.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nature and frequency of adverse events occurring over the trial period
Time Frame: Trial period of 36 weeks
|
Primary endpoint
|
Trial period of 36 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joanna Porter, MD, Respiratory Medicine, University College Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VP-C21-005
- 2020-000822-24 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on C21
-
Vicore Pharma ABCompletedCOVID-19Philippines, United States, Brazil, India, Russian Federation, Colombia, Argentina, Czechia, South Africa, Ukraine
-
Vicore Pharma ABOrphan ReachCompleted
-
Vicore Pharma ABCompletedEndothelial Dysfunction | Type2diabetesSweden
-
Vicore Pharma ABSGS Life Sciences, a division of SGS Belgium NVCompleted
-
Vicore Pharma ABCTC Clinical Trial Consultants ABCompleted